Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The ...

Clinical Trials

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: tasimelteon
Drug: Rifampin
Drug: Ketoconazole

First Posted Date: 2012-07-11

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT01637636

Locations: 🇺🇸
QPS Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Evaluation of the Pharmacodynamic and Pharmacokinetic Interactions of Tasimelteon and Ethanol

Phase 1

Completed

Conditions: Pharmacodyamics and Pharmacokinetics of Tasimelteon Alone and in Combination With Ethanol

Interventions: Drug: tasimelteon
Drug: Placebo ethanol
Other: Placebo tasimelteon
Drug: Ethanol

First Posted Date: 2012-04-16

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT01578057

Locations: 🇨🇦
INC Research Toronto, Inc., Toronto, Ontario, Canada

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon
Drug: Fluvoxamine

First Posted Date: 2012-02-28

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01540500

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: Tasimelteon

First Posted Date: 2012-02-06

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 32

Registration Number: NCT01526746

Locations: 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Tolerability and Pharmacokinetics of Iloperidone in Adolescent Patients

Phase 1

Completed

Conditions: Safety and Tolerability of Iloperidone

Interventions: Drug: iloperidone (oral tablet)

First Posted Date: 2011-12-19

Last Posted Date: 2016-06-13

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT01495169

Locations: 🇺🇸
Novartis Investigative Site, Salt Lake City, Utah, United States

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon

First Posted Date: 2011-11-22

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT01477619

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Phase 3

Completed

Conditions: Non-24-Hour Sleep-Wake Disorder

Interventions: Drug: tasimelteon
Drug: Placebo

First Posted Date: 2011-09-08

Last Posted Date: 2014-10-10

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT01430754

Locations: 🇺🇸
PAB Clinical Research Inc., Brandon, Florida, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Todd J. Swick, M.D., P.A., Houston, Texas, United States

and more 19 locations

Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: placebo
Drug: tasimelteon

First Posted Date: 2011-09-05

Last Posted Date: 2015-06-19

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 507

Registration Number: NCT01428661

Locations: 🇺🇸
Vanda Investigational Site, Brown Deer, Wisconsin, United States

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Phase 3

Completed

Conditions: Non-24-Hour Sleep-Wake Disorder

Interventions: Drug: tasimelteon

First Posted Date: 2011-09-05

Last Posted Date: 2015-04-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 200

Registration Number: NCT01429116

Locations: 🇺🇸
SleepMed, Inc. - Columbia, Columbia, South Carolina, United States
🇺🇸
SDS Clinical Trials Inc., Orange, California, United States
🇺🇸
VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area), Palo Alto, California, United States

and more 19 locations

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon
Drug: Rosiglitazone
Drug: Midazolam

First Posted Date: 2011-07-26

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01402076

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy